<DOC>
	<DOCNO>NCT01845831</DOCNO>
	<brief_summary>High blood glucose level hospitalize patient diabetes associate increased risk medical complication death . Improved glucose control insulin injection may improve clinical outcome prevent hospital complication . Glargine ( Lantus® ) insulin injection common treatment diabetes hospital . Sitagliptin ( Januvia® ) effective lower blood glucose . In recent pilot study aim determine difference glycemic control treatment sitagliptin ( Januvia® ) alone combination basal insulin basal bolus regimen general medicine surgery patient type 2 diabetes ( T2D ) . The investigator find treatment sitagliptin alone combination basal insulin result similar glycemic control compare basal bolus regimen . The investigator conduct prospective RCT aim determine safety efficacy sitagliptin therapy in-hospital post-discharge management general medicine surgical patient T2D . A total 280 patient know history diabetes randomize receive sitagliptin plus basal ( glargine ) insulin daily ( group 1 ) , basal bolus regimen glargine daily aspart lispro insulin meal ( group 2 ) . If need , patient treatment group receive correction dose rapid-acting insulin presence hyperglycemia ( BG &gt; 140 mg/dl ) . The overall hypothesis treatment sitagliptin combination basal insulin patient type 2 diabetes result similar improvement hospital post-discharge glycemic control lower frequency hypoglycemic event treatment basal bolus insulin regimen glargine daily lispro insulin meal . Patients recruit Grady Memorial Hospital , Emory University Hospital , University Michigan , Ohio State University Temple University</brief_summary>
	<brief_title>Sitagliptin Therapy Hospitalized Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Specific Aim 1 : To determine whether in-hospital glycemic control , measure mean daily blood glucose concentration frequency hypoglycemic event , different treatment sitagliptin ( Januvia® ) combination basal insulin ( glargine ) basal bolus regimen ( glargine rapid-acting insulin analog ) general medicine surgery patient T2D . Patients T2D treat diet and/or OAD low total daily dose insulin therapy ( ≤0.6 unit/kg/day ) randomize receive sitagliptin plus glargine insulin ( group 1 ) basal bolus regimen glargine daily rapid-acting insulin ( lispro aspart ) meal ( group 2 ) . If need , patient 2 treatment group receive supplemental ( correction ) dose rapid-acting insulin meal BG &gt; 140 mg/dl . Specific Aim 2 : To determine efficacy safety A1C base discharge algorithm control BG discharge patient T2D . Patients participate in-hospital ( Aim 1 ) arm invite enroll open label prospective outpatient study . The total duration study 6 month . Patients HbA1c ≤ 7 % discharge combination metformin sitagliptin ( Janumet ® ) twice daily . Those HbA1c 7 % 9 % discharge metformin sitagliptin ( Janumet ® ) twice daily plus glargine insulin 50 % inpatient glargine dose . Those HbA1c &gt; 9 % discharge metformin sitagliptin ( Janumet ® ) twice-daily plus glargine insulin 80 % inpatient dose .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Males female age 18 80 year admit medicine surgery service . 2 . A known history Type 2 Diabetes &gt; 1 month , receive either diet alone , oral antidiabetic agent : sulfonylurea metformin monotherapy combination therapy ( exclude DPP4 inhibitor ) lowdose ( ≤ 0.6 units/kg/day ) insulin therapy . 3 . Subjects blood glucose &gt; 140 mg &lt; 400 mg/dL time randomization without laboratory evidence diabetic ketoacidosis ( serum bicarbonate &lt; 18 mEq/L positive serum urinary ketone ) . 1 . Age &lt; 18 &gt; 80 year . 2 . Subjects increase BG concentration , without history diabetes ( stress hyperglycemia ) . 3 . Subjects history type 1 diabetes ( suggest BMI &lt; 25 require insulin therapy history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ) [ 46 ] . 4 . Treatment DPP4 inhibitor Glucagon like peptide 1 ( GLP1 ) analogs past 3 month prior admission . 5 . Acute critical illness coronary artery bypass graft ( CABG ) surgery expect require admission critical care unit . 6 . Subjects gastrointestinal obstruction adynamic ileus expect require gastrointestinal suction . 7 . Medical surgical patient expect kept NPO &gt; 2448 hour admission completion surgical procedure . 8 . Patients clinically relevant pancreatic gallbladder disease . 9 . Patients acute myocardial infarction , clinically significant hepatic disease significantly impair renal function ( GFR &lt; 30 ml/min ) . 10 . Treatment oral injectable corticosteroid = &gt; prednisone 5 mg/per day . 11 . Mental condition render subject unable understand nature , scope , possible consequence study . 12 . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Glargine</keyword>
	<keyword>RCT</keyword>
	<keyword>basal insulin</keyword>
	<keyword>hospital hyperglycemia</keyword>
	<keyword>inpatient diabetes</keyword>
</DOC>